The 41st Annual Meeting of the American Society of Clinical Oncology. Orlando, FL, USA, 13-17 May, 2005

Research output: Contribution to journalArticle

Abstract

Nearly 29,000 scientists from all over the world gathered at the 41st Annual Meeting of the American Society of Clinical Oncology (ASCO). The programme included the presentation of new data encompassing all the fields of cancer research, including cancer prevention, treatment and biology. Special sessions were added to summarise and discuss achievements in the field of translational research on biologically targeted therapies. Rational drug design based on tumour biology and genetics represents a promising strategy to overcome the limitations of conventional chemotherapy. Increased knowledge in the field of molecular oncology, genetics and progress in technology are revolutionising tumour classification, prognostication, prediction and therapy. However, at present, for most of the diseases, improvements brought about by the newer therapies are small, although clinically meaningful. This review will briefly address some of the most interesting data presented at ASCO 2005.

Original languageEnglish
Pages (from-to)2907-2921
Number of pages15
JournalExpert Opinion on Pharmacotherapy
Volume6
Issue number16
DOIs
Publication statusPublished - Dec 2005

Fingerprint

Neoplasms
Translational Medical Research
Medical Oncology
Drug Design
Therapeutics
Molecular Biology
Technology
Drug Therapy
Research

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

@article{3659be0ed3a24c388014273cea88b2e4,
title = "The 41st Annual Meeting of the American Society of Clinical Oncology. Orlando, FL, USA, 13-17 May, 2005",
abstract = "Nearly 29,000 scientists from all over the world gathered at the 41st Annual Meeting of the American Society of Clinical Oncology (ASCO). The programme included the presentation of new data encompassing all the fields of cancer research, including cancer prevention, treatment and biology. Special sessions were added to summarise and discuss achievements in the field of translational research on biologically targeted therapies. Rational drug design based on tumour biology and genetics represents a promising strategy to overcome the limitations of conventional chemotherapy. Increased knowledge in the field of molecular oncology, genetics and progress in technology are revolutionising tumour classification, prognostication, prediction and therapy. However, at present, for most of the diseases, improvements brought about by the newer therapies are small, although clinically meaningful. This review will briefly address some of the most interesting data presented at ASCO 2005.",
author = "Filippo Montemurro and Giorgio Valabrega and Lucia Garetto and Sandra Aliberti and Giovanni Grignani and Cinzia Ortega and Francesco Leone and Riccardo Ponzone and Massimo Aglietta",
year = "2005",
month = "12",
doi = "10.1517/14656566.6.16.2907",
language = "English",
volume = "6",
pages = "2907--2921",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "16",

}

TY - JOUR

T1 - The 41st Annual Meeting of the American Society of Clinical Oncology. Orlando, FL, USA, 13-17 May, 2005

AU - Montemurro, Filippo

AU - Valabrega, Giorgio

AU - Garetto, Lucia

AU - Aliberti, Sandra

AU - Grignani, Giovanni

AU - Ortega, Cinzia

AU - Leone, Francesco

AU - Ponzone, Riccardo

AU - Aglietta, Massimo

PY - 2005/12

Y1 - 2005/12

N2 - Nearly 29,000 scientists from all over the world gathered at the 41st Annual Meeting of the American Society of Clinical Oncology (ASCO). The programme included the presentation of new data encompassing all the fields of cancer research, including cancer prevention, treatment and biology. Special sessions were added to summarise and discuss achievements in the field of translational research on biologically targeted therapies. Rational drug design based on tumour biology and genetics represents a promising strategy to overcome the limitations of conventional chemotherapy. Increased knowledge in the field of molecular oncology, genetics and progress in technology are revolutionising tumour classification, prognostication, prediction and therapy. However, at present, for most of the diseases, improvements brought about by the newer therapies are small, although clinically meaningful. This review will briefly address some of the most interesting data presented at ASCO 2005.

AB - Nearly 29,000 scientists from all over the world gathered at the 41st Annual Meeting of the American Society of Clinical Oncology (ASCO). The programme included the presentation of new data encompassing all the fields of cancer research, including cancer prevention, treatment and biology. Special sessions were added to summarise and discuss achievements in the field of translational research on biologically targeted therapies. Rational drug design based on tumour biology and genetics represents a promising strategy to overcome the limitations of conventional chemotherapy. Increased knowledge in the field of molecular oncology, genetics and progress in technology are revolutionising tumour classification, prognostication, prediction and therapy. However, at present, for most of the diseases, improvements brought about by the newer therapies are small, although clinically meaningful. This review will briefly address some of the most interesting data presented at ASCO 2005.

UR - http://www.scopus.com/inward/record.url?scp=29444432116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29444432116&partnerID=8YFLogxK

U2 - 10.1517/14656566.6.16.2907

DO - 10.1517/14656566.6.16.2907

M3 - Article

C2 - 16318441

AN - SCOPUS:29444432116

VL - 6

SP - 2907

EP - 2921

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 16

ER -